Verastem (VSTM) Peer Comparison

$7.38

$-0.01 (-0.14%)

As on 27-Aug-2026 16:00EDT

Market cap

$624 Mln

Revenue (TTM)

$88 Mln

P/E Ratio

--

P/B Ratio

12.3

Div. Yield

0 %

Edit

	Verastem (VSTM)	Ascendis Pharma A/S - ADR	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Market cap ($ Mln)	624	16,614	17,326	13,400	12,305
Revenue ($ Mln)	88	1,054	2,782	2,436	670
Net Profit ($ Mln)	-202.70	755.85	491.50	860.62	-319.95
Net Margin (%)	-231.59	71.69	17.67	35.33	-47.79
RoE (%)	-378.23	--	110.09	42.98	-71.14
Price to Earnings	--	19.38	36.49	17.01	--
Price-To-Book	12.35	10.05	39.43	7.27	26.44

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Verastem (VSTM)	Ascendis Pharma A/S - ADR	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Operating Revenue	87.53	1,054.37	2,782.29	2,435.92	669.50
Cost of Revenue	11.65	103.47	1,982.07	85.67	19.14
Gross Profit	25.62	588.53	760.62	2,236.43	829.45
Operating Expenses	235.67	841.45	216.81	1,378.74	895.93
Operating Profit (EBIT)	-159.80	109.45	583.40	971.51	-226.44
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-201.88	101.11	598.92	1,035.47	-252.08
Provision for Tax	0.82	-654.74	107.42	174.84	20.05
Profit after Tax (Net Income)	-202.70	755.85	491.50	860.62	-319.95
Minority Interest	0.00	0.00	0.00	0.00	-47.83
Consolidated Profit	0.00	0.00	0.00	0.00	0.00

Liabilities ($ Mln)

	Verastem (VSTM)	Ascendis Pharma A/S - ADR	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Shareholder's Funds	49.99	1,435.90	433.86	1,843.76	465.53
Minority Interest	0.00	0.00	0.00	0.00	-47.83
Non-Current Liabilities	78.40	384.48	187.89	288.55	1,362.63
Current Liabilities	78.13	464.70	1,435.43	361.93	283.35
Total Liabilities	246.44	1,302.02	1,975.47	2,844.42	1,385.30

Assets ($ Mln)

	Verastem (VSTM)	Ascendis Pharma A/S - ADR	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Non-Current Assets	30.36	895.24	1,006.90	1,243.41	440.60
Current Assets	176.16	1,389.84	1,050.29	1,250.82	1,671.41
Total Assets	246.44	1,302.02	1,975.47	2,844.42	1,385.30
Total Debt*	84.33	449.89	120.10	165.93	864.07
Net Current Assets	98.03	0.00	-385.14	888.90	1,388.07

Cashflow ($ Mln)

	Verastem (VSTM)	Ascendis Pharma A/S - ADR	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Cash From Operating Activities	-137.51	51.77	713.22	884.27	179.55
Cash Flow from Investing Activities	-9.62	-8.15	-31.14	350.44	-129.29
Cash from Financing Activities	263.31	34.89	-860.39	-969.59	74.01
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Verastem (VSTM)	Ascendis Pharma A/S - ADR	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
ROCE (%)	-284.18	-30.01	53.56	32.82	-0.17
ROE (%)	-378.23	163.18	110.09	42.98	-71.14
ROA (%)	-76.31	26.53	15.64	29.32	-16.12
EBIT Margin (%)	-229.33	5.73	21.13	31.04	-0.77
Net Margin (%)	-231.59	71.69	17.67	35.33	-47.79
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Verastem (VSTM)	Ascendis Pharma A/S - ADR	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Revenue Growth (%)	1,216.55	114.85	24.67	9.23	12.22
EBIT Growth (%)	-22.64	136.39	18.70	-3.99	93.17
Net Profit Growth (%)	-21.70	378.76	17.50	42.89	-115.58
EPS Growth (%)	31.89	353.27	26.84	50.42	-73.87
Book Value Growth (%)	2.52	816.12	164.02	-0.70	-13.57

Valuation Ratios

	Verastem (VSTM)	Ascendis Pharma A/S - ADR	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Price / Earnings	-3.07	-59.76	36.06	15.79	-2,869.63
Price / Book Value	11.26	-80.42	35.44	5.72	10.04
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-2.44	-121.54	28.08	12.44	25.04
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Verastem (VSTM)	Ascendis Pharma A/S - ADR	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Debt to Equity	1.53	0.00	0.00	0.00	1.77
Short term debt to equity ratio	0.13	0.05	0.00	0.00	0.09
Current Ratio	2.25	2.99	0.73	3.46	5.90
Quick Ratio	2.22	2.32	0.73	3.38	5.90
Interest Coverage	-135.78	1.62	--	--	-1.72

Operating Efficiency Ratios

	Verastem (VSTM)	Ascendis Pharma A/S - ADR	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Debtors to sales (%)	33.22	21.25	15.88	13.74	1.28
Asset Turnover	0.33	0.37	0.89	0.83	0.34
Receivable days	53.24	85.52	50.42	43.48	1.50
Inventory Days	63.18	1,056.70	--	96.17	--
Payable days	567.87	331.01	6.26	147.97	221.81
Cash Conversion Cycle	-451.44	811.21	--	-8.32	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly